Transdermal deferoxamine prevents pressure-induced diabetic ulcers. - Wikidata - awgldk - TriplyDB

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

http://www.wikidata.org/entity/Q34926164

about

Progenitor cell dysfunctions underlie some diabetic complications PKCδ inhibition normalizes the wound-healing capacity of diabetic human fibroblasts.Cell-permeable iron inhibits vascular endothelial growth factor receptor-2 signaling and tumor angiogenesis.Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice.Emerging drugs for the treatment of wound healing.Using biomaterials to rewire the process of wound repair.Roles of p300 and cyclic adenosine monophosphate response element binding protein in high glucose-induced hypoxia-inducible factor 1α inactivation under hypoxic conditions.Macro- and microvascular endothelial dysfunction in diabetes.Deferoxamine: potential novel topical therapeutic for chronic wounds.Deferoxamine-activated hypoxia-inducible factor-1 restores cardioprotective effects of sevoflurane postconditioning in diabetic rats.A rabbit model for assessment of volatile metabolite changes observed from skin: a pressure ulcer case study.Collagen barrier membranes do not adsorb hypoxia mimetic activity-Activity of gingival fibroblasts cultured directly on collagen barrier membranes loaded with hypoxia mimetic agents.Comparison of the Hydroxylase Inhibitor Dimethyloxalylglycine and the Iron Chelator Deferoxamine in Diabetic and Aged Wound Healing.Black, White, and Gray: Macrophages in Skin Repair and Disease Deferoxamine-Soaked Suture Improves Angiogenesis and Repair Potential After Acute Injury of the Chicken Achilles Tendon Iron Chelation with Transdermal Deferoxamine Accelerates Healing of Murine Sickle Cell Ulcers Co-delivery of deferoxamine and hydroxysafflor yellow A to accelerate diabetic wound healing via enhanced angiogenesis Wound Healing Research at the Hagey Laboratory for Pediatric Regenerative Medicine at Stanford University School of Medicine Targeting the Cellular “Oxygen Sensors”: Hypoxia Pre-Conditioning and Stabilization of Hypoxia-Inducible Factors

P2860

Q28086990-6E2600E7-3C57-41CF-BCAF-963CAFA10E42 Q36618518-8CAF4A76-0070-4D62-8D4D-38B6368B7A52 Q37662235-26F4A3C3-9571-47EF-9791-C858830CCD21 Q38291587-BA4DA748-CD42-4775-AC81-D8BA98FB7718 Q38364058-5B16DB5F-78D1-48DF-92F5-A552B80B063F Q38660331-0121C5A5-FCDE-4598-BAAF-109BBFDD37E0 Q38799649-044DF7B3-233D-4F43-9117-22D538A6F116 Q39065434-B5B42E7D-E14F-45C5-8C29-45072011AC5C Q46352750-CCD9AAD5-62FA-42B7-A418-3ED7FAC4F725 Q46402109-F1396366-CF3D-4157-A92F-180C00ACADC7 Q46628880-B6B264EF-FC5E-4674-A4CC-7615B1614EE7 Q53349927-4CAD6A04-BE9E-4A5A-A479-D88BB856030B Q54778336-CD17EA51-4552-4789-BA88-4935B4FF2309 Q57151173-B41FC6C6-1606-4AA1-8794-8E13121E0A34 Q58119888-FEE7C85C-A6B6-408B-AA78-190360BE0F3E Q58124109-C3781F40-3EB7-4069-8544-F59BF84A98E0 Q58549991-3DD3BA69-15BE-4FF8-A50B-1D416890B829 Q58806293-C7214968-B598-42B4-B3B1-C25E15525251 Q58942288-755BA36D-975D-4DF0-9EF9-871A27B25FEA

P2860

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

http://www.wikidata.org/entity/Q34926164

description

2014 nî lūn-bûn

@nan

2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@ast

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@en

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@nl

type

label

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@ast

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@en

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@nl

prefLabel

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@ast

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@en

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@nl

P1433

Q34926164-E36D149F-C9DF-4B2D-9E38-9AD0C151D1D7

P1476

Q34926164-C3348D2D-EBB9-458D-A084-0D9B56A7E0E5

P2093

Q34926164-05AB59B9-4F08-491F-A678-88B6C37A57BA

Q34926164-06949D22-EAC4-4988-9A57-22EFB945A9E7

Q34926164-54F45531-EE79-446D-A783-B9030E42AE1B

Q34926164-6EE91661-CF63-4AC5-9229-6E119BC9B02E

Q34926164-82379733-A74F-4E58-89EB-18086F6011AD

Q34926164-83038BB9-AC5F-4FB5-9641-DEECA8AF9B03

Q34926164-86703999-2797-4930-A2B7-C687D0A3744D

Q34926164-94C1E328-1FE1-4BEB-8235-6B0BC558563D

Q34926164-A2E14107-6A3F-4954-A70E-E05A53714430

Q34926164-A5838174-D07B-41BD-9B93-844B60179B70

P2860

Q34926164-040AECB5-A1A1-4A9B-BE7B-AC69CDB55829

Q34926164-04D667E1-597B-4661-97FE-F38A98E34A9B

Q34926164-05BE381C-3004-489E-A3BC-13F54BB19C9D

Q34926164-0E702C0D-7275-4A85-91C7-ED5387D3D511

Q34926164-0F953098-D300-4336-855D-3895E0A71E6C

Q34926164-1D78A982-AAD0-4F87-B1D2-763845218DE2

Q34926164-1DA38E23-D17E-4886-9822-557BB594813E

Q34926164-1DB66789-627C-40A7-BD86-900F41CC9769

Q34926164-1FFBAAFF-F153-4350-B1C9-505BD30D9432

Q34926164-22F92586-C557-4538-8818-C8014933F2EC

P304

Q34926164-AFBFED87-367E-460B-A3F3-8DEF43F23755

P31

Q34926164-55C7BBD9-3843-4CB8-B378-36577A2BB95F

P356

Q34926164-7E04C624-C9B7-4B86-B16F-ED44C58BE980

P407

Q34926164-30C9A408-5953-435B-AE87-16509C7A538B

P433

Q34926164-C5D882E5-1640-4678-ACCC-6379918763DE

P478

Q34926164-ED227675-058B-4BB8-A0CA-9CB10D29DB93

P50

Q34926164-65F003EC-583D-47EF-9FB1-E6D5E3B43ED3

Q34926164-AC611C42-3557-4F22-927A-3E3EE0DD6448

Q34926164-D15486E3-B9A1-448D-A519-79789F935455

Q34926164-F770455C-37AD-4815-A344-1548A73A9043

P577

Q34926164-7412EA26-62D1-4C87-A5B8-6FE4934926BB

P698

Q34926164-08C04856-AD92-4171-BEC0-3A4A70A58A9E

P932

Q34926164-AFAE2912-6EF9-441B-99E8-2ED6E9DB8B78

P356

PNAS.1413445112

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Transdermal deferoxamine prevents pressure-induced diabetic ulcers.

@en

P2093

Alexander J Whittam

http://www.w3.org/2001/XMLSchema#string

Andrey V Malkovskiy

http://www.w3.org/2001/XMLSchema#string

Arnetha J Whitmore

http://www.w3.org/2001/XMLSchema#string

Dominik Duscher

http://www.w3.org/2001/XMLSchema#string

Evgenios Neofytou

http://www.w3.org/2001/XMLSchema#string

Geoffrey C Gurtner

http://www.w3.org/2001/XMLSchema#string

Jayakumar Rajadas

http://www.w3.org/2001/XMLSchema#string

Michael Brownlee

http://www.w3.org/2001/XMLSchema#string

Michael G Galvez

http://www.w3.org/2001/XMLSchema#string

Michael Januszyk

http://www.w3.org/2001/XMLSchema#string

P2860

Economic costs of diabetes in the U.S. in 2012

Hydrocolloid dressings for healing diabetic foot ulcers

Foam dressings for healing diabetic foot ulcers

Systemic VHL gene functions and the VHL disease

Transdermal microconduits by microscission for drug delivery and sample acquisition

The system of care for the diabetic foot: objectives, outcomes, and opportunities

Biochemistry and molecular cell biology of diabetic complications

Disorders of iron metabolism

Becaplermin: recombinant platelet derived growth factor, a new treatment for healing diabetic foot ulcers

Understanding chronic wounds: a unifying hypothesis on their pathogenesis and implications for therapy

P304

94-99

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1413445112

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

112

http://www.w3.org/2001/XMLSchema#string

P50

Mohammed Inayathullah

Melanie Rodrigues

Graham G Walmsley

P577

2014-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25535360

http://www.w3.org/2001/XMLSchema#string

P932

4291638

http://www.w3.org/2001/XMLSchema#string